Updates in pancreatic neuroendocrine carcinoma

Susan Alsamarai, Steven K. Libutti, Muhammad Wasif Saif

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. Surgical resection remains the only potentially curative approach for primary tumors, and is also associated with a survival benefit for hepatic metastases as well. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year suggest that targeted agents may also play a role in advanced disease. Sunitinib, which targets VEGF-1, 2 and 3 and PDGF seems to be a well tolerated treatment for advanced tumors. The mTOR inhibitor everolimus when combined with the VEGF inhibitor bevacizumab, resulted in measurable responses. The combination of bevacizumab and cytotoxic chemotherapy also shows potential.

Original languageEnglish (US)
Pages (from-to)336-340
Number of pages5
JournalJournal of the Pancreas
Volume11
Issue number4
StatePublished - Jul 2010

Keywords

  • Bevacizumab
  • Neuroendocrine tumors
  • Sunitinib
  • mTOR protein

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Fingerprint Dive into the research topics of 'Updates in pancreatic neuroendocrine carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Alsamarai, S., Libutti, S. K., & Saif, M. W. (2010). Updates in pancreatic neuroendocrine carcinoma. Journal of the Pancreas, 11(4), 336-340.